- ODM-201
-
-
2026-07-24
- CAS:1297538-32-9
- Purity: 0.99
- ODM-201
-
- $1000.00
-
2026-07-24
- CAS:1297538-32-9
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 5000
- Darolutamide
-
- $45.00
-
2026-07-14
- CAS:1297538-32-9
- Purity: 99.79%
- Supply Ability: 10g
Related articles - Preparation of ODM-201
- ODM-201 is a new generation AR inhibitor with superior preclinical efficacy compared to enzalutamide and bicalutamide, it does....
- Nov 12，2019
|
| | ODM-201 Basic information |
| Product Name: | ODM-201 | | Synonyms: | ODM-201;N-[(1S)-2-[3-(3-Chloro-4-cyanophenyl)-1H-pyrazol-1-yl]-1-methylethyl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide;N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide;Darolutamide (ODM-201);ODM-201(BAY-1841788);CS-1565;N-{(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]propan-2-yl}-5-[(1RS)-1-hydroxyethyl]-1H-pyrazole-3-carboxamide;0DM021 | | CAS: | 1297538-32-9 | | MF: | C19H19ClN6O2 | | MW: | 398.85 | | EINECS: | 829-313-8 | | Product Categories: | API | | Mol File: | 1297538-32-9.mol |  |
| | ODM-201 Chemical Properties |
| Melting point | 169 - 171°C | | Boiling point | 719.5±60.0 °C(Predicted) | | density | 1.41±0.1 g/cm3(Predicted) | | storage temp. | -20°C Freezer, Under inert atmosphere | | solubility | DMSO (Slightly), Methanol (Slightly) | | pka | 11.10±0.10(Predicted) | | form | Solid | | color | White to Off-White | | InChIKey | BLIJXOOIHRSQRB-PXYINDEMSA-N | | SMILES | N1C(C(O)C)=CC(C(N[C@@H](C)CN2C=CC(C3=CC=C(C#N)C(Cl)=C3)=N2)=O)=N1 |
| | ODM-201 Usage And Synthesis |
| Description | ODM-201 is an androgen receptor (AR) antagonist (Ki = 11 nM). It inhibits AR transactivation in U2OS osteosarcoma cells expressing human wild-type and mutant ARs (IC50s = 65, 66, 1,500, and 1,782 nM for wild-type, ARF876L, ARW741L, and ART877A, respectively). ODM-201 prevents androgen-induced AR nuclear translocation in AR-overexpressing HS-HEK293 and LNCaP cells and suppresses androgen-induced proliferation of VCaP cells (IC50 = 230 nM). In vivo, ODM-201 (50 mg/kg per day) reduces tumor growth in a VCaP castrated mouse xenograft model. It also inhibits tumor growth without increasing serum testosterone levels in a VCaP intact mouse xenograft model. | | Description | ODM-201 is a novel androgen receptor (AR) inhibit designed to inhibit the growth of prostate cancer cells through binding to the AR to inhibit the testosterone-induced AR nuclear translocation. It is particularly used in patients with progressive metastatic castration-resistant prostate cancer. It is effective in inhibiting the activity of some mutant ARs emerging during antiandrogen therapies, including the F876L mutation version which is resistant to enzalutamide and ARN-509 (the second-generation antiandrogens).Therefore, it has potential to overcome the resistance issue occurring upon AR-targeted therapies. | | Uses | ODM-201 is a compound being used as a novel next-generation androgen receptor-directed therapy for prostate cancer. | | Biological Activity | As a ligand-dependent transcription factor, androgen receptor(AR) controls the expression of multiple genes involved in cell growth and survival. Darolutamide is able to inhibit multiple AR variants that confer resistance to first-generation antagonists. | | Synthesis | Synthesis of Darolutamide
 | | in vivo | Darolutamide (ODM-201) showes a significant antitumor activity with both doses, 50 mg/kg twice daily being more efficacious compared to castrated, untreated mice (p<0.001), which also showes inhibition of tumor growth (p<0.05) vs. castrated, untreated mice. Further, there is no sign of treatment-related toxicities; the body weights of mice treated with Darolutamide twice daily do not decrease significantly during the treatment[1]. | | References | Moilanen, Anu Maarit, et al. "Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies." Sci Rep 5.2(2015):12007.
Fizazi, Karim, et al. "ODM-201, a new generation androgen receptor inhibitor for castration-resistant prostate cancer: Preclinical and phase I data." Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of 2013.
Fizazi, K, et al. "Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial." Lancet Oncology 5.9(2014):975-85. |
| | ODM-201 Preparation Products And Raw materials |
|